RU2019140828A - ЛИГАНДНОЕ СОЕДИНЕНИЕ α7-НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ЕГО ПРИМЕНЕНИЕ - Google Patents
ЛИГАНДНОЕ СОЕДИНЕНИЕ α7-НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ЕГО ПРИМЕНЕНИЕ Download PDFInfo
- Publication number
- RU2019140828A RU2019140828A RU2019140828A RU2019140828A RU2019140828A RU 2019140828 A RU2019140828 A RU 2019140828A RU 2019140828 A RU2019140828 A RU 2019140828A RU 2019140828 A RU2019140828 A RU 2019140828A RU 2019140828 A RU2019140828 A RU 2019140828A
- Authority
- RU
- Russia
- Prior art keywords
- acetylcholine receptor
- ligand compound
- nicotinic acetylcholine
- dementia
- halogen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Radiology & Medical Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (18)
1. Лигандное соединение α7-никотинового ацетилхолинового рецептора, представленное любой из следующих общих формул
где
R7 представляет собой галоген;
(2) R2 представляет собой водород, и R3 представляет собой галоген или аминогруппу; или R3 представляет собой водород, и R2 представляет собой галоген или аминогруппу;
2. Лигандное соединение α7-никотинового ацетилхолинового рецептора по п. 1, где галоген является меченным радиоактивным изотопом или является немеченным радиоактивным изотопом.
3. Лигандное соединение α7-никотинового ацетилхолинового рецептора по п. 2, где галоген представляет собой F или 18F.
4. Лигандное соединение α7-никотинового ацетилхолинового рецептора по п. 3, где его структурная формула является следующей:
5. Лигандное соединение α7-никотинового ацетилхолинового рецептора по любому из пп. 1-4, где лигандное соединение применяется в качестве агониста α7-никотинового ацетилхолинового рецептора.
6. Лигандное соединение α7-никотинового ацетилхолинового рецептора по любому из пп. 1-4, где лигандное соединение применяется в качестве частичного агониста α7-никотинового ацетилхолинового рецептора.
7. Применение лигандного соединения α7-никотинового ацетилхолинового рецептора по любому из пп. 1-4 для получения лекарственного препарата для профилактики или лечения когнитивных расстройств.
8. Применение лигандного соединения α7-никотинового ацетилхолинового рецептора по п. 4 в качестве средства визуализации ПЭТ.
9. Фармацевтическая композиция для профилактики или лечения когнитивных расстройств, содержащая терапевтически эффективное количество лигандного соединения α7-никотинового ацетилхолинового рецептора по любому из пп. 1-4 и фармацевтически приемлемый носитель.
10. Фармацевтическая композиция по п. 9, где когнитивные расстройства представляют собой по меньшей мере одно, выбранное из группы, состоящей из: пресенильной деменции, пресенильной болезни Альцгеймера, сенильной деменции, деменции альцгеймеровского типа, деменции с тельцами Леви, обусловленной микроинфарктами деменции, связанной со СПИДом деменции, связанной с ВИЧ деменцией, связанной с тельцами Леви деменции, связанной с синдромом Дауна деменции, болезни Пика, умеренного когнитивного расстройства, связанного с возрастом нарушения памяти, нарушения краткосрочной памяти, связанного с возрастом когнитивного расстройства, связанного с лекарственными препаратами когнитивного расстройства, связанного с синдром иммунодефицита когнитивного расстройства, связанного с сосудистыми заболеваниями когнитивного расстройства, шизофрении, синдрома дефицита внимания, синдрома дефицита внимания с гиперактивностью (ADHD) и дефицита научения.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710395513.0 | 2017-05-27 | ||
CN201710395513.0A CN107188900B (zh) | 2017-05-27 | 2017-05-27 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
PCT/CN2017/087339 WO2018218696A1 (zh) | 2017-05-27 | 2017-06-06 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2019140828A3 RU2019140828A3 (ru) | 2021-06-11 |
RU2019140828A true RU2019140828A (ru) | 2021-06-11 |
RU2756604C2 RU2756604C2 (ru) | 2021-10-04 |
Family
ID=59876106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2019140828A RU2756604C2 (ru) | 2017-05-27 | 2017-06-06 | ЛИГАНДНОЕ СОЕДИНЕНИЕ α7-НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ЕГО ПРИМЕНЕНИЕ |
Country Status (8)
Country | Link |
---|---|
US (1) | US20200147243A1 (ru) |
EP (1) | EP3632918B1 (ru) |
JP (1) | JP6912602B2 (ru) |
KR (1) | KR102356040B1 (ru) |
CN (1) | CN107188900B (ru) |
AU (1) | AU2017416647B2 (ru) |
RU (1) | RU2756604C2 (ru) |
WO (1) | WO2018218696A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108676007B (zh) * | 2018-06-22 | 2020-06-26 | 厦门大学 | 放射性核素标记的苯并蝶啶类衍生物及其制备方法和应用 |
CN109988173A (zh) * | 2019-04-03 | 2019-07-09 | 北京师范大学 | 芴酮类α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
WO2022255915A1 (en) * | 2021-06-01 | 2022-12-08 | Agneta Nordberg | Pet radiotracers |
CN113387867B (zh) * | 2021-07-15 | 2023-03-14 | 南华大学 | 一种氨基甲酸酯类邻氨基苯甲酸色胺衍生物及其制备与应用 |
CN114804990B (zh) * | 2022-04-18 | 2023-07-28 | 北京师范大学 | 一种季铵盐类化合物及其制备方法和应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2791678B1 (fr) * | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de 1,4-diazabicyclo [3.2.2] nonane-4-carboxylates et -carboxamides, leur preparation et leur application en therapeutique |
FR2809730B1 (fr) * | 2000-05-31 | 2002-07-19 | Sanofi Synthelabo | Derives de 1,4-diazabicyclo[3.2.2] nonanebenzoxazole, -benzothiazole et -benzimidazole, leur preparation et leur application therapeutique |
US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
ATE348829T1 (de) * | 2001-02-06 | 2007-01-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen zur behandlung von störungen des zns oder anderen erkrankungen |
US20050065178A1 (en) * | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
US7399765B2 (en) * | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
US7365193B2 (en) * | 2004-02-04 | 2008-04-29 | Abbott Laboratories | Amino-substituted tricyclic derivatives and methods of use |
US20050171079A1 (en) * | 2004-02-04 | 2005-08-04 | Schrimpf Michael R. | Amino-substituted tricyclic derivatives and methods of use |
SE0400970D0 (sv) * | 2004-04-14 | 2004-04-14 | Astrazeneca Ab | Nicotinic acetylcholine receptor ligands |
JP2008519820A (ja) * | 2004-11-15 | 2008-06-12 | ファイザー・プロダクツ・インク | Cns障害の治療のためのアザベンゾオキサゾール |
WO2006051413A1 (en) * | 2004-11-15 | 2006-05-18 | Pfizer Inc. | Azabenoxazoles for the treatment of cns disorders |
CA2587461A1 (en) * | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
AR055111A1 (es) * | 2005-08-08 | 2007-08-08 | Pfizer Prod Inc | Sal benzoato de 4-(5-metiloxazolo (4,5-metiloxazolo (4,5- b]piridin -2-il) -1,4- diabiciclo (3.2.2) nonano |
ATE478869T1 (de) * | 2006-02-14 | 2010-09-15 | Neurosearch As | Diazabicycloalkan-derivate und ihre medizinische verwendung |
US20090118265A1 (en) * | 2006-05-23 | 2009-05-07 | Dan Peters | Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
CN102300574A (zh) * | 2009-01-26 | 2011-12-28 | 神经研究公司 | 新的吲哚基-*二唑基-二氮杂二环壬烷衍生物及它们的医药和诊断用途 |
EP2768507B1 (en) * | 2011-10-20 | 2019-12-11 | Novartis AG | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
CN104262348B (zh) * | 2014-08-15 | 2017-12-15 | 北京师范大学 | 一种α7烟碱型乙酰胆碱受体配体及其制备方法 |
US20160235869A1 (en) * | 2015-02-13 | 2016-08-18 | The Johns Hopkins University | DERIVATIVES OF DIBENZOTHIOPHENE IMAGING OF alpha-7 NICOTINIC ACETYLCHOLINE RECEPTORS |
-
2017
- 2017-05-27 CN CN201710395513.0A patent/CN107188900B/zh active Active
- 2017-06-06 RU RU2019140828A patent/RU2756604C2/ru active
- 2017-06-06 US US16/617,851 patent/US20200147243A1/en not_active Abandoned
- 2017-06-06 JP JP2019565232A patent/JP6912602B2/ja active Active
- 2017-06-06 WO PCT/CN2017/087339 patent/WO2018218696A1/zh active Application Filing
- 2017-06-06 KR KR1020197038361A patent/KR102356040B1/ko active IP Right Grant
- 2017-06-06 AU AU2017416647A patent/AU2017416647B2/en active Active
- 2017-06-06 EP EP17911514.2A patent/EP3632918B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018218696A1 (zh) | 2018-12-06 |
EP3632918B1 (en) | 2023-12-20 |
EP3632918A4 (en) | 2020-07-29 |
EP3632918A1 (en) | 2020-04-08 |
KR102356040B1 (ko) | 2022-01-26 |
RU2756604C2 (ru) | 2021-10-04 |
JP6912602B2 (ja) | 2021-08-04 |
AU2017416647A1 (en) | 2020-01-16 |
EP3632918C0 (en) | 2023-12-20 |
JP2020523292A (ja) | 2020-08-06 |
KR20200013702A (ko) | 2020-02-07 |
RU2019140828A3 (ru) | 2021-06-11 |
AU2017416647B2 (en) | 2020-10-15 |
US20200147243A1 (en) | 2020-05-14 |
CN107188900B (zh) | 2019-09-06 |
CN107188900A (zh) | 2017-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2019140828A (ru) | ЛИГАНДНОЕ СОЕДИНЕНИЕ α7-НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И ЕГО ПРИМЕНЕНИЕ | |
DE602004010787T2 (de) | 3-substitutierte-2(arylalkyl)-1-azabicycloalkane und methoden zu deren verwendung | |
JP2020507602A5 (ru) | ||
MX2019014368A (es) | Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica. | |
UY29421A1 (es) | Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones. | |
ATE455776T1 (de) | Nikotinische alpha-7-rezeptorliganden gegen erkrankungen des zns | |
SA112330303B1 (ar) | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه | |
CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
SG162732A1 (en) | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine h3 - receptor ligands | |
UY29389A1 (es) | Derivados sustituidos del ácido1-((4-((((3,3-dimetil-2-oxo-2,3-dihidro-1h-indol-1-il)carbonil)amino)metil)piperidin-1-il)metil)ciclobutanocarboxílico, sales farmaceuticamente aceptables, composiciones que los contienen y aplicaciones. | |
UY28961A1 (es) | Derivados de ácido carboxílico de bencimidazolona antecedentes de la invención | |
US9403761B2 (en) | Aminocarbonylcarbamate compounds | |
RU2396264C2 (ru) | Производные хромана и их применение в качестве лигандов 5-нт рецептора | |
MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
JP2009538910A5 (ru) | ||
PE20071023A1 (es) | Azaciclilaminas-n-sustituidas como antagonistas de histamina-3 | |
JP2015531764A5 (ru) | ||
MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
DE60312226T2 (de) | Tetrazyklische 3-substituierte indole mit serotoninrezeptoraffinität | |
KR920006357A (ko) | 면역억제제로서 유용한 카르보시클릭 아데노신 동족체 | |
JPH0262883A (ja) | 新規スピローオキサチオラン/キヌクリジン化合物、それらの化合物を含有する薬剤組成物およびそれらを使用する中枢神経系の病気の治療法 | |
EA200701856A1 (ru) | Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении | |
MX2010004300A (es) | Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad. | |
RU2007125380A (ru) | Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний | |
ATE486078T1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors |